CHMP recommends EU approval of a new formulation of Roche’'s MabThera for patients with non-Hodgkin lymphoma

Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve MabThera (rituximab) 1400mg solution for subcutaneous (SC) injection for the treatment of patients with common forms of non-Hodgkin lymphoma (NHL).
Source: Roche Media News - Category: Pharmaceuticals Source Type: news